antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»10.37489/0235-2990-2025-70-9-10-29-35XEACZJantibiotics-1291Research ArticleЭКСПЕРИМЕНТАЛЬНЫЕ СТАТЬИExperimental ResearchЧастота резистентности к деламаниду у Mycobacterium tuberculosis, выделенных от больных туберкулёзом лёгких в Российской ФедерацииFrequency of Resistance to Delamanid in Mycobacterium tuberculosis Isolated from Patients with Pulmonary Tuberculosis in the Russian Federationhttps://orcid.org/0000-0002-4589-6133АндреевскаяС. Н.AndreevskayaS. N.

Андреевская Софья Николаевна — к. м. н., ведущий научный сотрудник отдела микробиологии

Москва

Sofya N. Andreevskaya — Ph. D in Medicine, Leading Researcher at the Department of Microbiology

 Moscow

andsofia@mail.ruhttps://orcid.org/0000-0003-2886-1745СмирноваТ.  Г.SmirnovaT. G.

Смирнова Татьяна Геннадьевна — к. м. н., ведущий научный сотрудник отдела микробиологии

Москва

Tatiana G. Smirnova — Ph. D in Medicine, Leading Researcher at the Department of Microbiology

 Moscow

https://orcid.org/0000-0002-6032-175XЛарионоваЕ.  Е.LarionovaE. E.

Ларионова Елена Евгеньевна — к. б. н., старший научный сотрудник отдела микробиологии 

Москва

Elena E. Larionova — Ph. D. in Biology, Senior Researcher at the Department of Microbiology

Moscow

https://orcid.org/0000-0002-3296-407XКиселеваЕ. А.KiselevaE. A.

Киселева Екатерина Андреевна — лаборант-исследователь отдела микробиологии

 Москва

Ekaterina A. Kiseleva — Laboratory Research Assistant at the Department of Microbiology

Moscow

МасленниковаЮ.  В.MaslennikovaYu. V.

Масленникова Юлия Васильевна — лаборант-исследователь отдела микробиологии 

 Москва

Yulia V. Maslennikova — Laboratory Research Assistant at the Department of Microbiology

Moscow

https://orcid.org/0000-0001-6288-7549ЧерноусоваЛ.  Н.ChernousovaL. N.

Черноусова Лариса Николаевна — д. б. н., профессор, главный научный сотрудник отдела микробиологии 

Москва

Larisa N. Chernousova — D. Sc. in Biology, Professor, Chief Researcher at the Department of Microbiology

Moscow

https://orcid.org/0000-0002-2494-9275ЭргешовА.  Э.ErgeshovA. E.

Эргешов Атаджан Эргешович — д. м. н., профессор, член-корреспондент РАН, директор; профессор кафедры фтизиатрии и пульмонологии 

Москва

Atadzhan E. Ergeshov — D. Sc. in Medicine, Professor, Corresponding Member of the Russian Academy of Sciences, Director ; Professor at the Department of Phthisiology and Pulmonology

Moscow

ФГБНУ «Центральный научно-исследовательский институт туберкулёза» Минобрнауки РоссииРоссияCentral Tuberculosis Research Institute of the Ministry of Science and Higher EducationRussian Federation«Центральный научно-исследовательский институт туберкулёза» Минобрнауки РоссииРоссияCentral Tuberculosis Research Institute of the Ministry of Science and Higher EducationRussian FederationФГБНУ «Центральный научно-исследовательский институт туберкулёза»; ФГБУ ВО «Российский университет медицины»РоссияCentral Tuberculosis Research Institute of the Ministry of Science and Higher Education of the Russian Federation; The Russian University of Medicine of the Ministry of HealthRussian Federation202530102025709-102935Copyright © Андреевская С.Н., Смирнова Т.Г., Ларионова Е.Е., Киселева Е.А., Масленникова Ю.В., Черноусова Л.Н., Эргешов А. ., 20262026Андреевская С.Н., Смирнова Т.Г., Ларионова Е.Е., Киселева Е.А., Масленникова Ю.В., Черноусова Л.Н., Эргешов А. .Andreevskaya S.N., Smirnova T.G., Larionova E.E., Kiseleva E.A., Maslennikova Y.V., Chernousova L.N., Ergeshov A.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.antibiotics-chemotherapy.ru/jour/article/view/1291

Деламанид — один из ключевых новых препаратов для лечения туберкулёза с множественной и, особенно, широкой лекарственной устойчивостью возбудителя, однако, ввиду его относительно недавнего внедрения в клиническую практику, данных о частоте выявления устойчивости к этому препарату недостаточно. Цель исследования: определить фенотипическую чувствительность к деламаниду Mycobacterium tuberculosis, выделенных от пациентов с туберкулёзом лёгких из Российской Федерации. Материал и методы. Исследован 271 изолят M. tuberculosis, выделенный от пациентов (2022–2025 гг.), отличающийся по характеру резистентности. Устойчивость к деламаниду (чистая субстанция Otsuka Pharmaceutical Co., Ltd., Япония) определяли модифицированным методом пропорций в системе BACTEC MGIT 960, критическая концентрация деламанида — 0,06 мкг/мл. Результаты. Устойчивость к деламаниду была выявлена в 14,39% (39/271) случаев как у изолятов M. tuberculosis, чувствительных к другим противотуберкулёзным препаратам, так и у M. tuberculosis со спектрами резистентности, включающими от 1 до 10 препаратов (не учитывая деламанид). Частота выявления устойчивости к деламаниду у M. tuberculosis с сохранённой чувствительность к рифампицину и у M. tuberculosis с множественной/широкой лекарственной устойчивостью достоверно не отличалась и составила 11,49 и 15,76% соответственно. Первичная устойчивость к деламаниду была определена не менее чем в 10/271 (3,69%) случаях. Заключение. Полученные данные свидетельствуют о значительном уровне распространения устойчивости к деламаниду, в том числе у изолятов, не подвергавшихся воздействию этого препарата. Следовательно, необходимо совершенствовать меры контроля за распространением устойчивых к этому препарату возбудителей.

Delamanid is one of the key new drugs for the treatment of multidrug-resistant and, in particular, extensively drug-resistant tuberculosis. However, due to its relatively recent introduction into clinical practice, data on the frequencу of resistance detection to this drug remain limited. The aim of the study was to determine the phenotypic susceptibility of Mycobacterium tuberculosis, isolated from patients with pulmonary tuberculosis in the Russian Federation, to delamanid. Materials and methods. The study included a total of 271 M. tuberculosis isolates with different resistance pat terns, obtained from patients in the Russian Federation (2022–2025). Resistance to delamanid (pure substance, Otsuka Pharmaceutical Co., Ltd., Japan) was determined using a modified proportional assay in the BACTEC MGIT 960 system; the critical concentration for delamanid was 0.06 µg/mL. Results. Resistance to delamanid was detected in 14.39% (39/271) of cases in both M. tuberculosis isolates susceptible to other anti-tuberculosis drugs and M. tuberculosis isolates with resistance profiles including 1 to 10 drugs (excluding delamanid). The incidence of delamanid resistance in M. tuberculosis with retained susceptibility to rifampin and in M. tuberculosis with multidrug/extensive drug resistance did not differ significantly, amounting to 11.49% and 15.76%, respectively. Primary resistance to delamanid was detected in at least 3.69% (10/271) of the cases. Conclusion. The data obtained indicate a significant level of resistance to delamanid, including among isolates not exposed to the drug. Therefore, it is imperative to improve measures to control the spread of pathogens resistant to this antimicrobial agent.

деламанидтуберкулёзмикобактерии туберкулёзамножественная лекарственная устойчивостьширокая лекарственная устойчивостьпервичная резистентностьdelamanidtuberculosisMycobacterium tuberculosismultidrug resistanceextensive drug resistanceprimary resistanceРабота выполнена на бюджетной основе в рамках НИР ФГБНУ «ЦНИИТ» «Комплексный подход к проблеме устойчивости M. tuberculosis к деламаниду: частота выявления, механизмы, синергизм»ReferencesGlobal tuberculosis report 2024. Geneva: World Health Organization; 2024.Global tuberculosis report 2024. Geneva: World Health Organization; 2024.Яблонский П. К., Вишневский Б. И., Соловьева Н. С., Галкин В. Б. Частота и структура лекарственной устойчивости M. tuberculosis при туберкулёзе легких и внелёгочной локализации. Туберкулёз и болезни лёгких. 2024; 102 (1): 40–45. doi: https://doi.org/0.58838/2075-1230-2024-102-1-40-45.Yablonskiy P. K., Vishnevskiy B. I., Solovyova N. S., Galkin V. B. Frequency and structure of drug resistance of M. tuberculosis in pulmonary and extrapulmonary tuberculosis. Tuberculosis and Lung Diseases. 2024; 102 (1): 40–45. doi: https://doi.org/0.58838/2075-1230-2024-102-1-40-45. (in Russian)]WHO consolidated guidelines on tuberculosis. Module 4: treatment — drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022.WHO consolidated guidelines on tuberculosis. Module 4: treatment — drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022.Saliu O. Y., Crismale C., Schwander S. K., Wallis R. S. Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis. J Antimicrob Chemother. 2007; 60 (5): 994–8. doi: 10.1093/jac/dkm291Saliu O. Y., Crismale C., Schwander S. K., Wallis R. S. Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis. J Antimicrob Chemother. 2007; 60 (5): 994–8. doi: 10.1093/jac/dkm291Igarashi M. Development of new antituberculosis drugs from natural products. Biosci Biotechnol Biochem. 2017; 81 (1): 32–37. doi: 10.1080/09168451.2016.1248369.Igarashi M. Development of new antituberculosis drugs from natural products. Biosci Biotechnol Biochem. 2017; 81 (1): 32–37. doi: 10.1080/09168451.2016.1248369.Sasaki H., Haraguchi Y., Itotani M., Kuroda H., Hashizume H., Tomishige T. et al. Synthesis and antituberculosis activity of a Novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles. J Med Chem. 2006; 49 (26): 7854–60. doi: 10.1021/jm060957y.Sasaki H., Haraguchi Y., Itotani M., Kuroda H., Hashizume H., Tomishige T. et al. Synthesis and antituberculosis activity of a Novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles. J Med Chem. 2006; 49 (26): 7854–60. doi: 10.1021/jm060957y.Khoshnood S., Taki E., Sadeghifard N., Kaviar V. H., Haddadi M. H., Farshadzadeh Z. et al. Mechanism of action, resistance, synergism, and clinical implications of delamanid against multidrug-resistant Mycobacterium tuberculosis. Front Microbiol. 2021; 12: 717045. doi: 10.3389/fmicb.2021.717045.Khoshnood S., Taki E., Sadeghifard N., Kaviar V. H., Haddadi M. H., Farshadzadeh Z. et al. Mechanism of action, resistance, synergism, and clinical implications of delamanid against multidrug-resistant Mycobacterium tuberculosis. Front Microbiol. 2021; 12: 717045. doi: 10.3389/fmicb.2021.717045.Greening C., Ahmed F. H., Mohamed A. E., Lee B. M., Pandey G., Warden A. C. et al. Physiology, biochemistry, and applications of F420- and fodependent redox reactions. Microbiol Mol Biol Rev. 2016; 80 (2): 451–93. doi: 10.1128/MMBR.00070-15.Greening C., Ahmed F. H., Mohamed A. E., Lee B. M., Pandey G., Warden A. C. et al. Physiology, biochemistry, and applications of F420- and fodependent redox reactions. Microbiol Mol Biol Rev. 2016; 80 (2): 451–93. doi: 10.1128/MMBR.00070-15.Matsumoto M., Hashizume H., Tomishige T., Kawasaki M., Tsubouchi H., Sasaki H. et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006; 3 (11): e466. doi: 10.1371/journal.pmed.0030466.Matsumoto M., Hashizume H., Tomishige T., Kawasaki M., Tsubouchi H., Sasaki H. et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006; 3 (11): e466. doi: 10.1371/journal.pmed.0030466.Singh R., Manjunatha U., Boshoff H. I., Ha Y. H., Niyomrattanakit P., Ledwidge R. et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science. 2008; 322 (5906): 1392–5. doi: 10.1126/science.1164571.Singh R., Manjunatha U., Boshoff H. I., Ha Y. H., Niyomrattanakit P., Ledwidge R. et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science. 2008; 322 (5906): 1392–5. doi: 10.1126/science.1164571.Kumar D., Negi B., Rawat D. S. The anti-tuberculosis agents under development and the challenges ahead. Future Med Chem. 2015; 7 (15): 1981–2003. doi: 10.4155/fmc.15.128.Kumar D., Negi B., Rawat D. S. The anti-tuberculosis agents under development and the challenges ahead. Future Med Chem. 2015; 7 (15): 1981–2003. doi: 10.4155/fmc.15.128.Manjunatha U., Boshoff H. I., Barry C. E. The mechanism of action of PA-824: novel insights from transcriptional profiling. Commun Integr Biol. 2009; 2 (3): 215–8. doi: 10.4161/cib.2.3.7926.Manjunatha U., Boshoff H. I., Barry C. E. The mechanism of action of PA-824: novel insights from transcriptional profiling. Commun Integr Biol. 2009; 2 (3): 215–8. doi: 10.4161/cib.2.3.7926.Chen X., Hashizume H., Tomishige T., Nakamura I., Matsuba M., Fujiwara et al.M. et al. Delamanid kills dormant Mycobacteria in vitro and in a guinea pig model of tuberculosis. Antimicrob Agents Chemother. 2017; 61 (6): e02402–16. doi: 10.1128/AAC.02402-16.Chen X., Hashizume H., Tomishige T., Nakamura I., Matsuba M., Fujiwara et al.M. et al. Delamanid kills dormant Mycobacteria in vitro and in a guinea pig model of tuberculosis. Antimicrob Agents Chemother. 2017; 61 (6): e02402–16. doi: 10.1128/AAC.02402-16.Szumowski J. D., Lynch J. B. Profile of delamanid for the treatment of multidrug-resistant tuberculosis. Drug Des Devel Ther. 2015; 9: 677–682. doi: 10.2147/DDDT.S60923.Szumowski J. D., Lynch J. B. Profile of delamanid for the treatment of multidrug-resistant tuberculosis. Drug Des Devel Ther. 2015; 9: 677–682. doi: 10.2147/DDDT.S60923.Stinson K., Kurepina N., Venter A., Fujiwara M., Kawasaki M., Timm J. et al. MIC of delamanid (OPC-67683) against Mycobacterium tuberculosis clinical isolates and a proposed critical concentration. Antimicrob Agents Chemother. 2016; 60 (6): 3316–22. doi: 10.1128/AAC.03014-15.Stinson K., Kurepina N., Venter A., Fujiwara M., Kawasaki M., Timm J. et al. MIC of delamanid (OPC-67683) against Mycobacterium tuberculosis clinical isolates and a proposed critical concentration. Antimicrob Agents Chemother. 2016; 60 (6): 3316–22. doi: 10.1128/AAC.03014-15.Wen S., Jing W., Zhang T., Zong Z., Xue Y., Shang Y. et al. Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis. 2019; 38 (7): 1293–1296. doi: 10.1007/s10096-019-03551-w.Wen S., Jing W., Zhang T., Zong Z., Xue Y., Shang Y. et al. Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis. 2019; 38 (7): 1293–1296. doi: 10.1007/s10096-019-03551-w.Yang J. S., Kim K. J., Choi H., Lee S. H. Delamanid, bedaquiline, and linezolid minimum inhibitory concentration distributions and resistance-related gene mutations in multidrug-resistant and extensively drug-resistant tuberculosis in Korea. Ann Lab Med. 2018; 38 (6): 563-568. doi: 10.3343/alm.2018.38.6.563.Yang J. S., Kim K. J., Choi H., Lee S. H. Delamanid, bedaquiline, and linezolid minimum inhibitory concentration distributions and resistance-related gene mutations in multidrug-resistant and extensively drug-resistant tuberculosis in Korea. Ann Lab Med. 2018; 38 (6): 563-568. doi: 10.3343/alm.2018.38.6.563.Diacon A. H., Dawson R., Hanekom M., Narunsky K., Venter A., Hittel N. et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis. 2011; 15 (7): 949–54. doi: 10.5588/ijtld.10.0616.Diacon A. H., Dawson R., Hanekom M., Narunsky K., Venter A., Hittel N. et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis. 2011; 15 (7): 949–54. doi: 10.5588/ijtld.10.0616.Gler M. T., Skripconoka V., Sanchez-Garavito E., Xiao H., Cabrera-Rivero J. L., Vargas-Vasquez D. E. et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012; 366 (23): 2151–60. doi: 10.1056/NEJMoa1112433.Gler M. T., Skripconoka V., Sanchez-Garavito E., Xiao H., Cabrera-Rivero J. L., Vargas-Vasquez D. E. et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012; 366 (23): 2151–60. doi: 10.1056/NEJMoa1112433.Von Groote-Bidlingmaier F., Patientia R., Sanchez E., Balanag V. Jr., Ticona E., Segura P. et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respir Med. 2019; 7 (3): 249–259. doi: 10.1016/S2213-2600(18)30426-0.Von Groote-Bidlingmaier F., Patientia R., Sanchez E., Balanag V. Jr., Ticona E., Segura P. et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respir Med. 2019; 7 (3): 249–259. doi: 10.1016/S2213-2600(18)30426-0.Skripconoka V., Danilovits M., Pehme L., Tomson T., Skenders G., Kummik T. et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J. 2013; 41 (6): 1393–400. doi: 10.1183/09031936.00125812.Skripconoka V., Danilovits M., Pehme L., Tomson T., Skenders G., Kummik T. et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J. 2013; 41 (6): 1393–400. doi: 10.1183/09031936.00125812.Technical Report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. Geneva: World Health Organization; 2018.Technical Report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. Geneva: World Health Organization; 2018.Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. Geneva: World Health Organization; 2018.Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. Geneva: World Health Organization; 2018.Ryan N. J., Lo J. H. Delamanid: first global approval. Drugs. 2014; 74 (9): 1041–5. doi: 10.1007/s40265-014-0241-5.Ryan N. J., Lo J. H. Delamanid: first global approval. Drugs. 2014; 74 (9): 1041–5. doi: 10.1007/s40265-014-0241-5.Maryandyshev A., Pontali E., Tiberi S., Akkerman O., Ganatra S., Sadutshang T. D. et al. Bedaquiline and delamanid combination treatment of 5 patients with pulmonary extensively drug-resistant tuberculosis. Emerg Infect Dis. 2017; 23 (10): 1718–21. doi: 10.3201/eid2310.170834.Maryandyshev A., Pontali E., Tiberi S., Akkerman O., Ganatra S., Sadutshang T. D. et al. Bedaquiline and delamanid combination treatment of 5 patients with pulmonary extensively drug-resistant tuberculosis. Emerg Infect Dis. 2017; 23 (10): 1718–21. doi: 10.3201/eid2310.170834.Марьяндышев А. О., Лорсанов С. М., Хайдарханова З. Б., Хункарсултанов С. Б., Перхин Д. В., Свешникова О. М. и др. Результаты применения деламанида в лечении туберкулёза с множественной и широкой лекарственной устойчивостью возбудителя в Российской Федерации. Туберкулёз и болезни легких. 2019; 97 (11): 67–68. doi: https://doi.org/10.21292/2075-1230-2019-97-11-67-68.Maryandyshev A. O., Lorsanov S. M., Khaydarkhanova Z. B., Khunkarsultanov S. B., Perkhin D. V., Sveshnikova O. M. et al. Treatment outcomes of regimens containing delamanid within therapy of multiple and extensive drug resistant tuberculosis in the Russian Federation. Tuberculosis and Lung Diseases. 2019; 97 (11): 67–68. doi: https://doi.org/10.21292/2075-1230-2019-97-11-67-68. (in Russian)]Гайда А. И., Свешникова О. М., Верховая В. Н., Махмаева С. В., Никишова Е. И., Марьяндышев А. О. Лечение больных туберкулёзом с широкой лекарственной устойчивостью микобактерий с применением новых про тивотуберкулёзных препаратов в гражданском обществе Архангельской области. Туберкулёз и болезни легких. 2018; 96 (7): 5–10. doi: https://doi.org/10.21292/2075-1230-2018-96-7-5-10.Gayda A. I., Sveshnikova O. M., Verkhovaya V. N., Makhmaeva S. V., Nikishova E. I., Maryandyshev A. O. Treatment of tuberculosis patients with extensive drug resistance using new anti-tuberculosis drugs in the civilian community of Arkhangelsk region. Tuberculosis and Lung Diseases. 2018; 96 (7): 5–10. doi: https://doi.org/10.21292/2075-1230-2018-96-7-5-10. (in Russian)]Лорсанов С. М., Хайдарханова З. Б., Хункарсултанов С. Б. Опыт применения деламанида в Чеченской Республике. Туберкулёз и болезни лёгких. 2019; 97 (12): 62–63. doi: https://doi.org/10.21292/2075-1230-2019-97-12-62-63.Lorsanov S. M., Khaydarkhanova Z. B., Khunkarsultanov S. B. The experience of using delamanid in the Chechen Republic. Tuberculosis and Lung Diseases. 2019; 97 (12): 62–63. (in Russian)Зимина В. Н., Викторова И. Б. Деламанид — новый противотуберкулёзный препарат: применение, ограничения, перспективы. Туберкулёз и болезни лёгких. 2021; 99 (2): 58–66. doi: https://doi.org/10.21292/2075-1230-2021-99-2-58-66Zimina V. N., Viktorova I. B. Delamanid is a new anti-tuberculosis drug: use, limitations, and prospects. Tuberculosis and Lung Diseases. 2021; 99 (2): 58–66. doi: https://doi.org/10.21292/2075-1230-2021-99-2-58-66. (in Russian)]Schena E., Nedialkova L., Borroni E., Battaglia S., Cabibbe A. M., Niemann S. et al. Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTECTM MGITTM 960 system. J Antimicrob Chemother. 2016; 71 (6): 1532–9. doi: 10.1093/jac/dkw044.Schena E., Nedialkova L., Borroni E., Battaglia S., Cabibbe A. M., Niemann S. et al. Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTECTM MGITTM 960 system. J Antimicrob Chemother. 2016; 71 (6): 1532–9. doi: 10.1093/jac/dkw044.Pang Y., Zong Z., Huo F., Jing W., Ma Y, Dong L. et al. In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant tuberculosis in Beijing, China. Antimicrob Agents Chemother. 2017; 61 (10): e00900–17. doi: 10.1128/AAC.00900-17.Pang Y., Zong Z., Huo F., Jing W., Ma Y, Dong L. et al. In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant tuberculosis in Beijing, China. Antimicrob Agents Chemother. 2017; 61 (10): e00900–17. doi: 10.1128/AAC.00900-17.Lee T., Lee S. J., Jeon D., Lee H. Y., Kim H. J., Kang B. H. et al. Additional drug resistance in patients with multidrug-resistant tuberculosis in Korea: a multicenter study from 2010 to 2019. J Korean Med Sci. 2021; 36 (26): e174. doi: 10.3346/jkms.2021.36.e174.Lee T., Lee S. J., Jeon D., Lee H. Y., Kim H. J., Kang B. H. et al. Additional drug resistance in patients with multidrug-resistant tuberculosis in Korea: a multicenter study from 2010 to 2019. J Korean Med Sci. 2021; 36 (26): e174. doi: 10.3346/jkms.2021.36.e174.Михайлова Ю. Д., Макарова М. В., Крылова Л. Ю., Носова Е. Ю., Жиркова С. А., Уштанит А. И. и др. Изучение чувствительности Mycobacterium tuberculosis к деламаниду с использованием автоматизированной системы BACTECTM MGITTM 960. Туберкулёз и социально значимые заболевания. 2024; 12 (4): 25–35. doi: https://doi.org/10.54921/2413-0346-2024-12-4-25-35.Mikhailova Y. D., Makarova M. V., Krylova L. Y., Nosova E. Y., Zhirkova S. A., Ushtanit A. I. et al. Study of drug susceptibility of Mycobacterium tuberculosis to delamanid using BACTECTM MGITTM 960 automated system. Tuberculosis and Socially Significant Diseases. 2024; 12 (4): 25–35. doi: https://doi.org/10.54921/2413-0346-2024-12-4-25-35. (in Russian)

The authors declare that there are no conflicts of interest present.